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Abstract 
Plasminogen activator inhibitor-1 (PAI-1) is the most important inhibitor of tissue-type plasminogen activator (t-PA) in plasma and 
plays a major role in the regulation of fibrinolysis. Plasma t-PA/PAI-I complexes are cleared via a receptor-dependent mechanism in 
hepatocytes, while the fate ef complexes formed in the extracellular matrix and in thrombi s less well understood. In this study, the 
degradation of t-PA/PAI-I complexes by monocytes was examined. THP-I monocytoid cells and freshly isolated human monocytes 
internalize and degrade [125I]t-PA/PAI-1 complexes at rates of 11.4 + 5.9 (mean +_ S.D.) and 44.6 + 6.3 ng/106 cells/h, respectively. 
Degradation is blocked by receptor-associated protein (RAP), indicating amember of the low density lipoprotein (LDL) receptor family is 
involved in the uptake/degradation of t-PA/PAI-1 complexes by monocytes. Degradation of t-PA/PAI-1 complexes i also inhibited by 
chloroquine and by pepstatin A, suggesting that a lysosomal aspartyl protease is likely involved. SDS-PAGE and Western blotting 
demonstrated that the purifed lysosomal aspartyl protease, cathepsin D, is capable of digesting t-PA (t~/2 15 min), active PAI-1 (t~/2 2 
h), and t-PA/PAI-1 comple~ (tl/2 30 min). Cathepsin D sequentially cleaves PAI-I after hydrophobic amino acids, yielding lower 
molecular weight fragments. PAl-1 conformation i fluences the degradative efficiency of cathepsin D, with vitronectin-bound PAl-1 and 
latent PAI-I exhibiting resistance to proteolysis and > 10-fold prolongation i  t~/2. These data provide evidence that t-PA/PAI-I 
complexes are internalized by human monocytes via a member of the low density lipoprotein (LDL) receptor family, and identifies 
cathepsin D-like aspartyl protease activity as largely responsible for the degradation of these complexes. Furthermore, vitronectin-bound 
PAI-1 and latent PAI-I are :relatively resistant to degradation by cathepsin D, which may be of importance in complex physiological 
environments. 
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1. Introduction 
Plasmin is the major protease of the fibrinolytic system 
[ 1 ] and plays an important role in cell migration and tissue 
Abbreviations: LRP, low density lipoprotein receptor-related protein; 
PAl-l, plasminogen activator inhibitor-l; PAI-2, plasminogen activator 
inhibitor-2; RAP, receptor-associated protein; SDS-PAGE, sodium dode- 
cyl sulfate polyacrylamide g l electrophoresis; SEC, serpin-enzyme com- 
plex; TBS, Tris-buffered saline; TCA, trichloroacetic a id; t-PA, tissue- 
type plasminogen activator; u-PA, urokinase-type lasminogen activator. 
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remodelling [2] by virtue of the fact that it is capable of 
degrading extracellular matrix proteins directly or indi- 
rectly via the activation of metalloproteases [3]. Plasmin is 
derived from plasminogen by the endogenous plasminogen 
activators, tissue-type plasminogen activator (t-PA) [4] and 
urokinase-type plasminogen activators (u-PAs) [5]. 
The generation of plasmin is regulated by a balance 
between the plasminogen activators, t-PA and u-PA, and 
their specific inhibitors, plasminogen activator inhibitor-1 
(PAl-l) [6-9] and plasminogen activator inhibitor-2 (PAl- 
2) [10-13]. Two functionally distinct forms of PAl-l, 
termed active and latent, have been identified [14]. In 
plasma, most of the PAI-1 circulates in the active form 
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[15], which deactivates spontaneously with a tl/2 of 1-2 h 
[16] and is stabilized by vitronectin [17]. 
Active PAI-1 acts as a suicide substrate for t-PA and 
u-PA and rapidly neutralizes these plasminogen activators 
by forming a covalent complex [18]. The liver is the major 
site of t-PA clearance [19,20], and it has been demon- 
strated that the formation of t-PA/PAI-1 complex plays a 
critical role in the clearance of t-PA by hepatocytes [21- 
24]. Receptor-mediated binding and endocytosis of t- 
PA/PAI-1 complex by hepatocytes is mediated by the low 
density lipoprotein receptor-related protein (LRP) [24,25]. 
There is also evidence that the serpin-enzyme complex 
(SEC) receptor [26,27] and urokinase receptor (indirectly 
via LRP) [28] may also participate in the clearance of 
plasminogen activator-PAl- 1 complex. 
While hepatocytes may be important in the clearance of 
circulating t-PA/PAI-1 complex, the fate of t-PA/PAI-1 
complex in the extravascular space is less well charac- 
terized. PAI-1 is present in the vascular wall [29] and 
accumulates in neointimal cells within atherosclerotic hu- 
man arteries [30]. In addition, platelets contain large stores 
of PAl-1 which are released with platelet activation [31,32] 
and become incorporated into thrombi by virtue of the fact 
that PAl-1 binds to fibrin and inhibits t-PA-mediated fibrin 
dissolution [33,34]. 
The monocyte plays an important role in the fibrinolytic 
system. The monocyte coordinates the assembly of plas- 
minogen and monocyte-secreted plasminogen activators 
[35] on surface receptors [36-38], which enhances the 
catalytic efficiency of plasmin generation. The monocyte 
accumulates within the thrombus and vessel wall and 
possesses the potentially relevant receptors (i.e., LRP, 
SEC, and uPAR) required for the binding and endocytosis 
of plasminogen activator-PAI-1 complex. We therefore 
considered the possibility that monocytes may play a direct 
role in the degradation and clearance of t-PA/PAI-1. 
Immortalized human monocytoid cells and human mono- 
cytes were used to characterize the catabolism of t- 
PA/PAI-1. We found that t-PA/PAI-1 complex is inter- 
nalized by human monocytes and degraded via a cathepsin 
D-like lysosomal aspartyl protease. 
2. Materials and methods 
bodies to t-PA (2G6 and 1C8 directed to the active site or 
fibrin binding domains of t-PA, respectively) and PAl-1 
(7F5 and 15H12) were kindly provided by Drs. Paul J. 
Declerck and Drsir6 Collen (University of Leuven, Leu- 
ven, Belgium). Goat anti-mouse Ig (horseradish peroxi- 
dase-linked) was purchased from Cal-Biochem (La Jolla, 
CA). Urea-treated human vitronectin was supplied by Dr. 
Harold Chapman (Brigham and Women's Hospital, Boston, 
MA). Receptor-associated protein (RAP) was a gift of Dr. 
Anders Nykjaer (University of Aarhus, Aarhus, Denmark). 
2.2. Cells 
The monocytic cell line THP-1 (American Type Culture 
Collection, Rockville, MD) was maintained in culture in 
RPMI 1640 containing 20% fetal calf serum, 20 mM 
hydroxyethylpiperazine ethanesulfonic a id (Hepes), and 2 
mM L-glutamine. Monocyte-enriched mononuclear (> 
85%) cells were prepared from whole blood via continuous 
density gradient separation using Sepracell-MN, as previ- 
ously described [39]. Cells were counted with a Coulter 
Counter, Model ZM (Hialeah, FL). 
2.3. Protein labelling 
Recombinant human t-PA and PAI-1 were radiolabelled 
with [125I] using iodo-beads, as previously described [40]. 
The specific activity of [lZSI]t-PA and [I25I]PAI-1 ranged 
from 1-2.105 cpm//~g; total radioactivity was greater 
than 98% trichloroacetic a id (TCA)-precipitable. t-PA and 
PAI-1 were iodinated to this relatively low specific activity 
in order to limit oxidative damage and preserve functional 
activity [41]. In order to assess the ability of iodinated t-PA 
and PAl to form [t25I]t-PA/PAI-1 or t-PA/[125I]PAI-I 
complexes, 100 nM [125I]t-PA or [125I]PAI-1 were added 
to 200 nM PAI-1 or t-PA, respectively, in Tris-buffered 
saline (TBS) (pH 7.4), consisting of 10 mM tris(hydroxy- 
methyl)aminomethane d 150 mM NaCI, for 60 min at 
37 ° C, and then subjected to sodium polyacrylamide gel 
electrophoresis (SDS-PAGE) for autoradiography (Fig. 1). 
Densitometry using Image software (NIH, Bethesda, MD) 
indicated that approx. 90% of [~25I]t-PA and 60% of 
[125I]PAI-1 are capable of forming t-PA/PAI-1 com- 
plexes. 
2.1. Special reagents 2.4. t-PA / PAL1 degradation assays 
Ammonium chloride, cathepsin D, chloroquine, E64D, 
leupeptin, and pepstatin A were purchased from Sigma (St. 
Louis, MO). Tissue-type plasminogen activator (t-PA) was 
a generous gift of Genentech (South San Francisco, CA. 
Sepracell-MN was purchased from Sepratech (Oklahoma 
City, OK). S-2288 was purchased from Pharmacia-Hepar 
(Franklin, OH). Recombinant human PAI-1 (predomi- 
nantly active) was kindly provided by Dr. Thomas Reilly 
(DuPont-Merck, Wilmington, Delaware). Monoclonal anti- 
The degradation of [125I]t-PA/PAI-I or t- 
PA/[125I]PAI-1 complexes by THP-1 cells and human 
monocytes was examined as previously described in detail 
[39]. Briefly, THP-1 cells and human monocytes were 
washed and resuspended at 1.0-107/ml in serum-free 
RPMI. t-PA/PAI-1 complexes were formed by the addi- 
tion of 100 nM t-PA to I00 nM PAI-I in TBS (pH 7.4) for 
60 min at 37°C. Fifty nM [125I]t-PA/PAI-1 or t- 
PA/[125I]PAI-1 complex was then added to 1-1.5-106 
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Fig. 1. t-PA/PAI-1 complex formation by [12sI]t-PA or [125I]PAI-1. In 
order to assess the ability of iodinated t-PA and PAI to form [125I]t- 
PA/PAI-1 or t-PA/[125I]PAI-1 complexes, 100 nM [125I]t-PA or 
[1251]PAI-I were added to 200 nM PAI-1 or t-PA, respectively, in TBS 
(pH 7.4) for 60 rain at 37°C and then subjected to SDS-PAGE for 
autoradiography. Densitometry indicated that approx. 90% of [12sl]t-PA 
and 60% of [125I]PAI-1 are capable of forming t-PA/PAI-1 complexes, 
respectively. 
monocytoid cells in serurn-free RPMI at 37 ° C. After 120 
min, ice-cold TCA (final concentration 10%) was added 
and the incubation mixture was then centrifuged at 12 000 
× g for 4 min in an Eppendorf microfuge. An aliquot of 
supernatant was then counted to determine the amount of 
acid-soluble radioactive material generated by the cells, 
i.e., [125I]-labeled iodotyrosine-containing peptides. In or- 
der to exclude a nonspecific uptake and degradation mech- 
anism, i.e., nonreceptor-mediated pinocytosis/phago- 
cytosis, degradation (nonspecific) was determined in the 
presence of a 20-fold molar excess of unlabeled t-PA-PAI- 1 
complex. Specific degradation (total-nonspecific) is ex- 
pressed as ng of [125I]t-PA or [~25I]PAI-1 protein degraded 
per 10 6 cells per h. Nonspecific degradation accounted for 
approx. 40% of total degradation. In order to examine the 
time courses of [12sI]t-PA/PAI-1 or t-PA/[~25I]PAI-1 
degradation, aliquots were also removed at 1, 2, 4, 8, and 
24 h. 
To elucidate the mechanism of t-PA/PAI- 1 degradation 
by monocytoid cells, incubations were performed in the 
presence of 50 ~g/ml  RAP, 100 /xM chloroquine, 5 mM 
NH4C1, 1 mM leupeptin, 100 /xM E64D, and 1 mM 
pepstatin A. Relative degradation was calculated from the 
ratio of the rate of degradation i the presence of inhibitor 
to the rate in the absence of inhibitor. Percent inhibition is 
calculated from the equation 100 - (relative degradation X 
100). 
(molecular weight = 46 000 Da and two chain (molecular 
weight 12000 and 34000 Da) forms of cathepsin D. The 
cleavage patterns of proteolysis by cathepsin D was inves- 
tigated using SDS-PAGE. Active PAl-l, latent PAI-1, 
PAI-1 bound to native or urea-treated human vitronectin, 
t-PA, and t-PA/PAI-1 complex were incubated with 400 
nM cathepsin D (enzyme-to-substrate io 1:5-10) in 100 
mM NaC1, 50 mM sodium acetate (pH 4.0) at 37 ° C. 
Latent PAI-1 was obtained by incubating active PAI-1 at 
37°C for 24 h. Vitronectin-bound PAI-I was formed by 
the addition of 100 /zg/ml PAI-1 to 100 /xg/ml urea- 
purifed human vitronectin. Aliquots were removed over 
time and the reaction was stopped by boiling for 5 min in 
sample buffer for electrophoresis containing 0.0625 M 
Tris-HC1 (pH 6.8), 10% glycerol, 2% sodium dodecyl 
sulfate, 0.0025% bromophenol blue, with or without 2% 
2-mercaptoethanol. t-PA, PAl-I, or t-PA/PAI-1 cleavage 
fragments were separated and analyzed by SDS-PAGE 
performed with 12.5% polyacrylamide slab gels using a 
discontinuous buffer system [43]. 
To quantify the relative susceptibilities of t-PA, active 
PAl- 1, latent PAl- 1, or vitronectin-bound PAl- 1 to proteol- 
ysis by cathepsin D, the above SDS-PAGE gels were 
transferred to Immobilon-P (Millipore, Bedford, MA) for 
standard Western blotting techniques. The primary anti- 
body consisted of a mixture of 2 monoclonal antibodies to 
PAI-1 or 2 monoclonal antibodies to t-PA; secondary 
antibody horseradish peroxidase-linked goat anti-mouse 
IgG 1:1000. The membrane was developed with 1 mg/ml 
diaminobenzadine i  a solution containing 2 mg/ml imi- 
dazole and 0.03% H202. The relative intensity of the 
intact 72 kDa t-PA, 45 kDa PAI-l, or 117 kDa t-PA/PAI-1 
complex bands were quantified over time using Image 
software (NIH, Bethesda, MD) and the ti/2 was then 
calculated from the plot of relative intensity versus time. 
To isolate PAI-1 fragments for aminoterminal sequence 
analysis, a terminal cathepsin D digest of PAI-1 was 
reduced with 45 mM dithioetheritol, alkylated with 100 
mM iodoacetamide, and then subjected to HPLC using a 
reverse-phase column developed with acetonitrile in 0.06% 
trifluoroacetic a id (0-100% over 70 min). Aminoterminal 
analysis of the isolated proteolytic fragments was per- 
formed on an Applied Biosystems 477A Protein Sequencer 
with an on-line phenylthiohydantoin-amino acidanalyzer 
(Harvard University Microchemistry Facility, Cambridge, 
MA, William Lane, Ph.D., Director). 
2.6. t-PA kinetic assays 
2.5. Cathepsin D proteolytic assays 
The ability of purified cathepsin D to cleave t-PA or 
PAI-1 was subsequently investigated. Bovine spleen 
cathepsin D, purifed with pepstatin-Sepharose a  previ- 
ously described [42], was used in these assays. This prepa- 
ration results in approximately equal mixtures of single 
The ability of PAl-l, before and after cathepsin D 
proteolysis, to inhibit t-PA activity was assessed using the 
chromogenic substrate S-2288. PAI-I (176 tzg/ml) was 
added to 800 nM cathepsin D in 100 mM NaCI, 50 mM 
sodium acetate (pH 4.0) or to buffer alone for 120 rain at 
25 ° C. Fifty nM PAI-1, treated with cathepsin D or buffer, 
was then added to 10 nM t-PA and 0.5 mM S-2288 in 50 
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Table 1 
t-PA/PAI-1 degradation by human monocytoid cells 
Cell ng [1251]t-PA / ng [J25I]PAI-1 / 
106 cells/h 106 cells/h 
THP-1 11.4_+5.9 5.1 ± 1.6 
PBMC 44.6 + 6.3 8.4 ± 1.6 
The degradation of [125I]t-PA/PAI-I and t-PA/[125I]PA1-1 complexes 
by THP-1 cells and monocyte-enriched peripheral blood mononuclear 
cells (PBMC) was investigated at 37 ° C. After 120 rain, ice-cold TCA 
was added and the incubation mixture was then centrifuged at 12 000 × g 
for 4 rain in an Eppendorf microfuge. An aliquot of supematant was then 
counted to determine the amount of acid-soluble radioactive material 
generated by the cells, i.e., [JzsI]-labeled iodotyrosine-containing pep- 
tides. Nonspecific degradation was determined in the presence of a 
20-fold molar excess of unlabeled t-PA/PAI-1 complex. Specific degra- 
dation (total-nonspecific) s expressed as ng of [IzsI]t-PA or [L~SI]PAI-1 
protein degraded per 106 cells per h (mean+S.D.; n= 3-11). 
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Fig. 2. Time course of t-PA/PAI-1 degradation by monocytoid cells. The 
time course of degradation was investigated using THP-I cells. Com- 
plexes of [t25I]t-PA/PAI-I (O) or t-PA/[t25I]PAI-1 (O) complex were 
added to 1.0-106 THP-I cells in serum-free RPMI at 37°C; aliquots 
were removed at 0, I, 2, 4, 8, and 24 h in order to assess degradation. 
Values represent the mean of two experiments performed in duplicate. 
mM Tris, 100 mM NaCI (pH 7.4), and t-PA activity was 
measured by recording OD405 nm over time. 
2.7. Statistical nalysis 
Results are presented as means + standard eviation 
(S.D.). Determination f statistical significance was carried 
out by Student's t-test or two-way analysis of variance 
followed by a post-hoc Newman-Keuls comparison. Val- 
ues of P < 0.05 were considered significant. 
3. Results 
3.1. Degradation of t-PA / PAL1 by monocytoid cells 
Immortalized THP-1 monocytoid cell line and periph- 
eral blood monocytes were used to characterize the prote- 
olytic degradation of t-PA/PAI-1 complexes. At 37°C, 
THP-1 monocytoid cells and human monocyte-enriched 
PBMCs internalize and degrade [t25I]t-PA/PAI-1 com- 
plexes at rates of 11.4 5.9 (mean_ S.D.) and 44.6 6.3 
ng/106 cells/h (Table 1). We also examined the uptake 
and degradation of the alternatively labelled t- 
PA/[125I]PAI-1 complex, which is degraded by THP-1 
cells and monocyte-enriched PBMCs at rates of 5.1 1.6 
and 8.4 1.6 ng/106 cells/h. The time course of t- 
PA/PAI-1 complex degradation by THP-1 cells was also 
investigated (Fig. 2). Degradation is linear over at least 8 
h, suggesting continuous t-PA/PAI-1 complex binding, 
internalization, and degradation. 
3.2. Mechanism of t-PA / PAL1 degradation by monocytes 
RAP, a 39 kDa protein, binds to members of the LDL 
receptor family (i.e., LRP, gp330, VLDL receptor, and 
LDL receptor) and inhibits the uptake and degradation of 
t-PA/PAI-1 by hepatocytes [24,25]. RAP blocked the 
degradation of t-PA/PAI-1 in THP-1 cells and PBMCs by 
88 + 20% (n = 3) and 84 ___ 21% (n = 3), respectively, 
indicating that a LDL receptor family member is involved 
in the uptake and degradation of t-PA/PAI-I complexes 
by monocytes. To identify the protease responsible for 
t-PA/PAI-1 degradation by monocytoid cells, incubations 
were performed in the presence of potential inhibitors (Fig. 
3). t-PA/PAI-1 degradation was significantly inhibited by 
chloroquine (85 + 16%, n = 7) and NH4CI (92 + 9%, n = 
5), suggesting that a lysosomal-dependent pathway is in- 
volved. The lysosomal cysteinyl protease inhibitor, E64D, 
failed to block degradation. The aspartyl protease inhibitor, 
pepstatin A, inhibited t-PA/PAI-I degradation by 76 + 
24% (n = 5). Given the pepstatin results demonstrating 
that lysosomal aspartyl protease activity is responsible for 
the degradation of t-PA/PAI-1, the enzymatic properties 
of purified cathepsin D, the human monocyte lysosomal 
aspartyl protease, toward t-PA and PAI-1 substrates were 
examined. 
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Fig. 3. Mechanism of t-PA/PAI-1 degradation. The degradation of 
t-PA/PAI-I by monocytoid cells was investigated at 37°C in the pres- 
ence of potential inhibitors. These included 100 p.M chloroquine, 5 mM 
NHaC1, 100 /zM E64D, and 1 mM pepstatin A. Relative degradation was 
calculated from the ratio of the rate of degradation i the presence of 
inhibitor to the rate in the absence of inhibitor. Each value represents he 
mean±S.D. (n= 3-7). 
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3.3. Susceptibility of PAl-1 and t-PA to proteolysis by (a) LANE 
cathepsin D k De 1 2 3 4 5 6 
PAI-1 exists in active and latent forms. In order to 
explore the relative susceptibil ity of  active versus latent 
PAI-1 to proteolysis by cathepsin D, we separated cathep- 
sin D digests of  active and latent PAI-1 with SDS-PAGE 
and quantitated relative PAI-1 antigen over t ime using 
Western blotting techniques as described in Section 2. A 
time course of proteolysis by cathepsin D is shown in Fig. 
106 , 
80 = 
49"--" 
33 
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(a) 
Active PAl-1 
Latent PAl-1 r~ *~ T 
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t-PA 
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Fig. 4. Susceptibilities of PAI-1 and t-PA to proteolysis by cathepsin D. 
The cleavage of PAI-1 and t-PA by cathepsin D was investigated using 
SDS-PAGE and Western blotting techniques. Active PAI-1 (O), latent 
PAL1 (0), active PAI-1 bound to urea-treated human vitronectin (•) ,  
and t-PA ( • ) were incubated with 400 nM cathepsin D (enzyme-to-sub- 
strate ratio l:10) in 100 rnM NaC1, 50 mM sodium acetate (pH 5.0) at 
37 ° C. Aliquots were removed over time for PAI-1 (0, 1, 2, 4, 24 h) or 
t-PA (0, 5, 15, 30 rain); cleavage fragments were then separated by 
SDS-PAGE performed under non-reducing conditions and transferred to 
Immobilon-P for Western blotting with PAl-1 or t-PA antibodies, respec- 
tively (a). The amount of PAI-l or t-PA degraded over time was assessed 
by determining the relative intensity of the 45 kDa or 72 kDa band, 
respectively, at the time indicated compared to time zero (b). The t]/2 
was calculated from the plot of relative intensity versus time. The 
cleavage of t-PA/PAI-1 complex (• )  by cathepsin D was also investi- 
gated under similar conditions. Aliquots were removed over time (0, 15, 
30, 60, 120 min) and cleavage fragments were then separated by SDS- 
PAGE performed under non-.reducing conditions The amount of t- 
PA/PAI-1 degraded over time was assessed by determining the relative 
intensity of 117 kDa band at the time indicated compared to time zero. 
27----~ 
0 15 30 60120 240 
(b) TIME (min) 
Seissile bond P2 P1 PI' P2' P3' P4' P5' 
43-44 Val Phe I Gh Gin Val Ala Gin 
105-106 Glu Leu Met Gly Pro Trp Asn 
162-163 Asp Trp Val Lys Thr His Thr 
247-248 Ile Leu Glu Leu Pro Tyr His 
277-278 Ile Leu Ser Ala Gin Leu lie 
Fig. 5. PAI-1 and its proteolytic fragments generated by cathepsin D. 
Cleavage of active PAI-1 by cathepsin D was performed by incubating 
PAI-1 with cathepsin D (enzyme-to-substrate r tio 1:5) at 37 ° C. A time 
course (0-240 min) was first examined by performing SDS-PAGE under 
reducing conditions (a). A terminal digestion of PAI-1 by cathepsin D 
was obtained by incubating PAI-1 with cathepsin D at 37°C overnight. 
To isolate fragments for aminoterminal sequence analysis, this terminal 
digest was reduced, alkylated, and then subjected to HPLC using a 
reverse-phase column. Five major peaks were identified and aminotermi- 
nal sequence analysis was subsequently performed (b). Actual sequence 
obtained spans Pi '-Ps' and cleavage sites were localized according to the 
published amino acid sequence of human PAI-1 [77]. The strongly 
favored hydrophobic residues at the Pi site, previously described for other 
cathepsin D substrates [44], are highlighted. 
4a,b. PAI-1 conformation influences the degradative ffi- 
ciency of  cathepsin D, with latent PAl-1 exhibiting resis- 
tance to proteolysis and greater than 10-fold prolongation 
in t i /2 (t l /2 for active PAI-1 2 h versus 24 h for latent 
PAI-1). Therefore, proteolytic leavage sites are apparently 
more accessible in the active PAI-1 conformation. 
The binding of  PAI-1 to vitronectin may play a role in 
maintaining the active conformation of PAI-1 in v ivo [17]. 
We therefore also investigated the effect of  PA I - I -  
vitronectin complex formation on the susceptibility of  
PAI-1 to proteolysis by cathepsin D (Fig. 4a,b). Act ive 
PAI-1 bound to native or urea-treated human vitronectin is 
rendered less susceptible to proteolysis by cathepsin D. 
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Purified cathepsin D rapidly digested t-PA (t~/2 15 
min). The increased egradative fficiency of purified 
cathepsin D toward t-PA compared to PAI-1 is consistent 
with the intact cell experiments (Table 1) demonstrating a 
2.2-and 5.3-fold increased uptake and degradation of 
[I25I]t-PA/PAI-1 compared to t-PA/[lzsI]PAI-1 com- 
plexes by THP-1 cells or PBMCs, respectively. 
The degradation of t-PA/PAI-1 complex by purified 
cathepsin D was also investigated by SDS-PAGE (Fig. 
4a,b). Cathepsin D rapidly cleaves the 117 kDa band 
corresponding to intact t-PA/PAI-1 complex (t~/2 30 
min). 
3.4. Characterization of PAI-1 cleavage products 
3.5. Fibrinolytic implications of PAl-1 cleavage by cathep- 
sin D 
In addition to the predominant intracellular localization 
of cathepsin D in lysosomes and endosomes, there are 
membrane-associated [45] and secreted pools of cathepsin 
D [46]. Given the abundance of PAl-1 in the extracellular 
matrix and the importance of PAI-1 in regulating local 
plasminogen activation by the plasminogen activators, 
u-PA and t-PA, the inhibitory potential of PAI-1 before 
and after exposure to cathepsin D was investigated. PAl-1 
is rapidly cleaved by cathepsin D (Fig. 5a), resulting in 
proteolytic fragments that are ineffective inhibitors of t-PA 
(Fig. 6). 
To identify the cleavage products of PAI- 1 generated by 
cathepsin D and to locate their cleavage sites, we separated 
digests of active PAI-1 with SDS-PAGE or HPLC and 
performed aminoterminal sequence analysis. A time course 
of proteolysis by cathepsin D is shown in Fig. 5a. Cleav- 
age of PAI-1 occurs rapidly with the generation of multi- 
ple lower-molecular weight fragments. To characterize 
representative cl avage sites, a reverse phase-HPLC sepa- 
ration of a terminal digest of PAl-1 was performed. The 
five major peaks were subjected to aminoterminal se- 
quence analysis identifying cleavage sites at residues 43- 
44, 105-106, 162-163, 247-248, and 277-278 (Fig. 5b). 
Cathepsin D cleaves PAl-1 after a hydrophobic 
(leu/aromatic) amino acid (PI), which conforms to the 
strongly favored sequence pattern of 'hydrophobic-hydro- 
phobic-charged-x-x-charged' for respective P1-P5 posi- 
tions, as previously reported for cathepsin D cleavage of 
other substrates [44]. 
~ 600- 
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Fig. 6. t-PA kinetic assays. The ability of PAI-1, before and after 
cathepsin D proteolysis, to inhibit t-PA activity was assessed using the 
chromogenic substrate S-2288. PAI-1 (176/zg/ml) was added to 800 nM 
cathepsin D in 100 mM, 50 mM sodium acetate (pH 4.0) or to buffer 
alone for 120 min at 25 ° C. Fifty nM PAl-l, treated with cathepsin D or 
buffer, was then added to 10 nM t-PA and 0.5 mM S-2288 in 50 mM 
"Iris, 100 mM NaCI (pH 7.4), and t-PA activity was measured by 
recording OD4o 5 nm over time. Values are expressed as mean + standard 
deviation, t-PA (0 )  vs. t-PA+CD/PAI- I  (11), P = 0.84; t-PA or t-PA 
+CD/PAI-1 vs. t-PA+PAI-1 (A), P < 0.01). 
4. Discussion 
This study provides evidence that t-PA/PAI-1 com- 
plexes are degraded by human monocytes via a pathway 
that requires a member of the LDL receptor family and a 
cathepsin D-like lysosomal aspartyl protease. We have 
characterized the enzymatic leavage of PAI-1 by the 
relevant human monocyte lysosomai aspartyl protease, 
cathepsin D, and have demonstrated a ifferential suscepti- 
bility of PAI-1 to proteolysis that is directly related to 
PAI-1 structure (i.e., active, latent, or complexed to vit- 
ronectin). 
The cellular pathway of t-PA/PAI-1 catabolism has 
been delineated in the well-differentiated human hepatoma 
cell line Hep G2 by several investigators. In this pathway, 
t-PA first complexes with PAI-1 that is associated with 
extracellular matrix vitronectin [47]. t-PA/PAI-1 complex 
is released from vitronectin [22] and then binds to a high 
affinity cellular receptor(s) [21-27]. This complex subse- 
quently undergoes receptor-mediated endocytosis [25,48] 
and is then delivered to lysosomes [49]. In addition to 
hepatoma cell lines, t-PA/PAI-1 catabolism has also been 
described in cultured smooth muscle cells from human 
umbilical cord [50], cultured human fibroblasts [51], and 
African green monkey COS kidney cells [25]. We have 
now identitified that cathepsin D-like lysosomal aspartyl 
protease activity is largely responsible for t-PA/PAI-1 
catabolism using human monocytoid cells/monocytes. 
Underhill and co-workers [46] have previously explored 
the catabolism of t-PA/PAI-1 complex in Hep G2 cells. 
After endocytosis and lysosomal delivery of [125I]t- 
PA/PAI- 1 or t-PA-[~25I]/PAI- 1, HepG2 cells degrade the 
individual components of the complex at markedly differ- 
ent rates. While t-PA is rapidly degraded at a rate of 
approx. 150 fmol/106 cells/100 min, PAI-1 persisted in 
lysosomes with only slow, partial degradation. Similarly, 
we have demonstrated that t-PA is degraded more rapidly 
(2.2-to 5.3-fold) than PAl-1. In contrast, we have observed 
that THP-1 cells (264 fmol/106 cells/100 min) and hu- 
man monocytes (1034 fmol/106 cells/100 min) are capa- 
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ble of digesting t-PA/PAI-1 complexes at significantly 
higher rates than HepG2 cells. While HepG2 cells may 
underestimate the rate of complex digestion by cultured 
primary hepatocytes, this study suggests that monocytes 
may possess a higher capacity clearance system that may 
be particularly relevant in the clearance of t-PA/PAI-1 
complexes formed in the extracellular matrix and in 
thrombi. 
The degradation rates for [125I]t-PA/PAI-1 and t- 
PA/[125I]PAI-I that we have reported may be limited by 
the fact that t-PA-PAI-1 complexes were not purified prior 
to monocyte addition. In 1:he design of monocyte degrada- 
tion studies, we intended to add a sufficient -PA/PAI-1 
complex concentration te saturate LRP, the receptor e- 
quired for complex digestion in HepG2 cells. Given the 
relatively high affinity of LRP for t-PA-PAI-1 complexes 
(kD < 10 nM) [25], we achieved a sufficient concentration 
to saturate LRP by adding 50 nM [125I]t-PA/PAI-1 or 
t-PA/[125I]PAI-1, the majority of which was in complexed 
form by SDS-PAGE. The affinity of LRP for uncomplexed 
t-PA and PAI-1 is significantly ower (kD > 30 nM) [24,47] 
and previous investigator,; have demonstrated insignificant 
degradation of uncomplexed t-PA [25]. We have confirmed 
the results of Orth et al. [25] and have performed egrada- 
tion experiments with uncomplexed t-PA and PAl-l, 
demonstrating rates of degradation only 18 + 4% (mean + 
S.D., n = 3) of that achieved with the addition of complex 
(data not shown). Therefore, the reported egradation rates 
likely reflect the degradation of [~25I]t-PA/PAI-1 and 
t-PA/[12SI]PAI-1, respectively. 
Two functionally distinct forms of PAl-l, termed active 
and latent, have been identified [14]. In plasma, most of 
the PAI-I circulates in active form [15,52], while latent 
PAI-1 is the predominant species isolated from platelets 
[53,54]. Active PAI-1 deactivates spontaneously at 37°C 
and latent PAI-1 can be n~activated in vivo by a fast-acting 
mechanism present in circulation that we have previously 
described [55]. The precise physiologic role(s) of distinct 
forms of PAI-1 is unknown. Interestingly, Carrell and 
co-workers previously hypothesized that functionally dis- 
tinct forms of PAl- 1 may result in a survival advantage for 
PAI-1 in complex physiologic environments by having a 
mobile reactive center that can vary exposure to prote- 
olytic attack [56]. This study now demonstrates that, under 
acidic conditions, PAI-1 conformation influences the 
degradative efficiency of cathepsin D, with latent PAI-I 
exhibiting resistance to proteolysis and greater than 10-fold 
prolongation i t~/2 (tl/2 for active PAI-1 2 h vs. 24 h for 
latent PAl-l). Vitronectin binding may also protect PAI-1 
from proteolytic cleavage. This finding suggests that active 
PAI-1 undergoes a conformational change when bound to 
vitronectin, as previously demonstrated by Reilly and col- 
leagues [57], that makes cathepsin D cleavage sites less 
accessible. Alternatively, vitronectin may sterically inter- 
fere with enzyme-substmte complex formation. The inter- 
pretation of experiments investigating the proteolytic sus- 
ceptibility of PAl-1 may be limited by the fact that they 
were performed under acidic conditions (pH 4.0), which 
may have altered PAl-1 conformation. However, in spec- 
troscopic studies examining the effect of pH on PAI-1 
structure, intrinsic fluorescence properties of latent and 
active PAI-1 revealed no significant changes in relative 
fluorescence down to pH 4.0 (data not shown). The physi- 
ologic significance of these observations regarding the 
proteolytic susceptibility of PAI-1 remains to be deter- 
mined. 
Protease inhibitor studies suggest hat lysosomal as- 
partyl protease activity contributes ignificantly to t- 
PA/PAI-1 degradation by human monocytes. We have 
focused our studies on cathepsin D because it is the only 
lysosomal aspartyl protease in human monocytes. While 
cathepsin E [58,59] is a closely related aspartyl protease 
with respect o size, substrate specificity, inhibition by 
pepstatin A, and dependence of enzmatic activity on acid 
pH, cathepsin E is present in rat leukocytes, but absent in 
human leukocytes and human leukemic cell lines [60]. 
Cathepsin D is a lysosomal aspartyl protease that functions 
within an acidic pH range [61]. A partial list of known 
substrates for cathepsin D includes hemoglobin [47], serum 
albumin [62], apolipoprotein B-100 [63], collagen [64], and 
fibrin(ogen) [65]. Widely distributed in human tissues, 
cathepsin D plays important physiologic roles in the lyso- 
somal catabolism of proteins and in the processing and 
activation of proteolytic enzymes (procathepsin B) [66], 
hormones (somatostatin) [67], and growth factors (transfor- 
ming growth factor-/3) [68]. 
In addition to the predominant intracellular localization 
of cathepsin D in lysosomes and endosomes, there are 
membrane-associated an secreted pools of cathepsin D, 
the function of which are unknown. Cathepsin D binds to 
the monocyte/macrophage mannose-6-phosphate receptor 
[44,45,69], which determines the sorting of cathepsin D 
between intracellular and plasma membrane components. 
Inflammatory mediators, such as 3,-interferon, markedly 
increase secreted cathepsin D activity in human 
macrophages [70]. In addition, human plasma contains 
measurable vels of cathepsin D (12 + 1 ng/ml, n = 26; 
unpublished data). 
The potential for extracellular cleavage of uncomplexed 
PAl-1 or t-PA by cathepsin D needs to be considered in 
light of the following observations. Pathophysiologically, 
cathepsin D has been implicated in tumor invasion and 
metastasis [71,72], owing to its ability to degrade xtracel- 
lular matrix [73]. Cathepsin D cleavage of PAI-1 would 
further enhance matrix remodelling by promoting plas- 
minogen activator activity which directly generates plas- 
min. The binding of cathepsin D to the mannose receptor 
may provide a mechanism for the release of cathepsin D in 
areas of inflammation or ischemia. Local regions of hyper- 
acidity form during inflammation as macrophages switch 
to glycolysis and secrete lactic acid resulting in pH 3.5-5.0 
[74,75]. Low pH is capable of resulting in ligand-mannose 
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receptor dissociation [76]. Nonetheless, the potential signif- 
icance of cathepsin D activity in the extracellular space 
may be limited by pH constraints of an aspartyl protease 
with an acidic pH optimum. 
In conclusion, these data provide evidence that t- 
PA/PAI-1 complexes are internalized by human mono- 
cytes via a member of the LDL receptor family, and 
identifies cathepsin D-like lysosomal aspartyl protease ac- 
tivity as largely responsible for the degradation of these 
complexes. Furthermore, vitronectin-bound PAI-1 and la- 
tent PAI-1 are resistant to degradation by cathepsin D and 
appear to enhance the survival of intact protein when faced 
with proteolytic attack, which may be of importance in 
complex physiological environments. 
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